From
StayCurrent Espanol
Un paso mas cerca del tratamiento de problemas del neurodesarrollo en pacientes con RCIU
hosted by Dr. Cecilia Gigena
Chapter 1 of 4
Introduction
Introduction to IUGR neurodevelopmental treatment research
Expert statements on this page
No expert statements were drawn from this page.
Host summaries · secondary, not cited in answers
Educational content from recorded physician discussions — not medical advice. Talk to your (or your child's) care team about your situation.
Video
Volumen testicular en la pubertad en niños con criptorquidia congénita aleatorizados a tratamiento en diferentes edades
1 min · Published Jul 2024
Video
Cuidado de transición en malformación anorrectal y enfermedad de Hirschsprung
1 min · Published Jul 2024
Video
Exploración laparoscópica trancística del conducto biliar común en pacientes pediátricos con coledocolitiasis
1 min · Published Jul 2024
Video
Características clínicas y pronóstico de la atresia de vías biliares con niveles bajos de metaloproteinasa 7 de la matriz sérica
55 s · Published Jul 2024
Video
Reglas de predicción PECARN para imágenes por TC de niños que acuden al servicio de urgencias con traumatismo craneoencefálico menor o abdominal cerrado
58 s · Published Jul 2024
Video
El cese del tratamiento con antibióticos para la apendicitis complicada en el momento del alta no aumenta el riesgo de infección posoperatoria
55 s · Published Jul 2024
What the experts said
The study was a preclinical study conducted at Boston Children's Hospital together with Harvard Medical School
The study objective was to determine if mesenchymal stem cell therapy via amniotic fluid could reduce brain inflammation in patients with intrauterine growth restriction
Researchers created a rat model of intrauterine growth restriction and divided subjects into four groups
Group 1 received no treatment, Group 2 received only saline solution, Group 3 received MSC therapy via amniotic fluid, and Group 4 received MSC therapy with a primer before the mesenchymal cells
Untreated patients and those who received only saline solution had significantly lower brain weight
Patients treated with mesenchymal stem cell therapy via amniotic fluid had greater brain weight
Patients who received MSC therapy via amniotic fluid with a primer had significantly less expression of interleukin-beta and TNF-alpha in the brain
Reduced expression of interleukin-beta and TNF-alpha indicates less brain inflammation